Compromise reached on COVID-19 vaccine patent waiver for developing nations
A compromise allows developing countries that exported less than 10% of global vaccine doses in 2021 to authorise patented vaccines without patent holder consent. The waiver applies only to vaccines, not therapeutics or diagnostics, and includes provisions for emergency measures and bundled patents.
Herald Premium Archive
This report is for subscribers
Sign in or choose a plan for full access to every Belfast Herald story and the complete archive.
HealthCompromise reached on COVID-19 vaccine patent waiver for developing nations
Sign in or subscribeBrowse free archive reportsA compromise allows developing countries that exported less than 10% of global vaccine doses in 2021 to authorise patented vaccines without patent holder consent. The waiver applies only to vaccines, not therapeutics or diagnostics, and includes provisions for emergency measures and bundled patents.